CONGRESS|#EHA2023 Matthew Frank Stanford Medicine discusses the safety and efficacy of CD22 CART therapy in pts with LBCL who have relapsed after CD19 CART therapy. The ORR and CR rates were 68% and 53%, respectively #lymphoma #lymsm #medicalcongress

MRD-NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS Mark Roschewski Foresight Diagnostics Inc. Jason Westin, MD FACP Ryan Lynch Stephen Opat NCI Center for Cancer Research MorphoSys onlinelibrary.wiley.com/doi/10.1002/ho…

🚨Next-level T cell engineering enters the clinic! DNA base editor to simultaneously silence CD7 (minimize fratricide), TCRB (minimize GVHD), and CD52 (host pre-conditioning) in allo CD7 CAR-expressing T cells for T-ALL. No DNA cuts, no translocations. nejm.org/doi/full/10.10…

👏🏾👏🏾 Glofitamab now FDA approved for R/R DLBCL after ≥2L | Fixed-duration Rx (~9mo) 👍🏾👍🏾which is desirable | Access is 🔑

“If you want to go fast go alone, if you want to go far, go together” I am incredibly proud to conclude this chapter alongside an immensely talented class of physicians. 🎉👩‍⚕️👨‍⚕️. The top of every mountain is the bottom of the next. Excited for the next phase MD Anderson Cancer Center

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes dlvr.it/SrNfnb

Navitoclax a B-cell lymphoma (BCL)-extra large (BCL-XL)/BCL-2 inhibitor for the treatment of MF | Kudos to Naveen Pemmaraju, MD and team👏🏾👏🏾

CD4+ CART are a driver of CRS in high tumor burden scenarios. cell.com/cell-reports-m…

Personal lessons learned from the MD Anderson MDS database. #mdssm

Given the differential efficacy of polatuzumab against DLBCL subtypes (on account of ABC-specific vulnerability of CD79b targeting and differential efficacy of the polatuzumab payload, MMAE) precision medicine is warranted for untreated DLBCL #lysm nejm.org/doi/full/10.10…

Do you remember the vigorous April 2023 discussion after #ODAC vote & #FDA approval of #polatuzumab for #DLBCL & #HGBCL? Well, with Adam C Palmer & Dave Kurtz, we now tackle this more through meta-analysis NEJM… 1/n nejm.org/doi/full/10.10…

Are all cytopenias after CAR-T created equal? We explored that question using the phenotypes of post-CAR neutrophil recovery as a blueprint to examine the pathophysiology of hematotoxicity and study its prognostic impact. Out today Science Advances 🎉 science.org/doi/10.1126/sc…

Big news day in #lymsm #lymphoma ! Congratulations Katharine Lewis Chan Cheah et al for leading this massive international effort High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma ascopubs.org/doi/10.1200/JC…

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas ashpublications.org/blood/article/…

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma ashpublications.org/blood/article-…

🧬🩸 Happy to share a review I wrote w/ Alex Herrera on ctDNA in DLBCL with a focus on applications (now and in the new future) for trials and in the clinic. We must aim high to incorporate ctDNA analysis to the routine care of pts #lymsm #ctDNA #MRD rdcu.be/dFGlj

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.10…

Phase 1 study: Anti-CD37 CAR-T cells in rel/ref CD37+ B and T-cell lymphoma. N=5, 3/5 achieved CR. 3/5 had profound pancytopenia requiring alloHCT in 2 patients #CARTcell Matthew Frigault Dr Marcela Maus #lymsm #bmtsm ashpublications.org/blood/article-…